Advances in the Treatment and Management of Myelodysplastic Syndrome (MDS): The Role of Oral HMAs

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs).

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

EP. 1: Diagnosing and Managing Myelodysplastic Syndrome

December 19th 2023

Join Dr. Guillermo Garcia-Manero in this OncLive Insights program as he delves into the latest advancements in the treatment of myelodysplastic syndrome (MDS), with a specific focus on the emerging role of oral hypomethylating agents (HMAs). In this episode, gain insights about MDS risk stratification and prognosis, and why it is important to treat early.

EP. 2: Treating Intermediate- and High-Risk MDS

January 4th 2024

The role of HMAs in the treatment of patients with intermediate- and high-risk MDS.

EP. 3: Available and Emerging Oral HMAs

January 4th 2024

Guillermo Garcia-Manero, MD, provides a high-level overview of the effectiveness of oral HMA agents in the treatment of intermediate- and high-risk MDS.

EP. 4: Real-World Use for Oral HMAs

January 11th 2024

An expert discusses the real-world impact of hypomethylating agents for the treatment of patients with MDS.

EP. 5: The Impact of Oral HMA Treatment Options on QOL

January 11th 2024

A review of the benefits of oral HMA treatments in the management of MDS, and the impact on a patient's quality of life.

EP. 6: The Role for HMAs in Lower-Risk MDS

January 18th 2024

An expert discusses data supporting the use of HMAs in the treatment of lower-risk MDS.

EP. 7: Treating CMML and AML with HMAs

January 18th 2024

An overview of how HMAs are being used to treat CMML and their use in combination with other therapies for patients with AML.

EP. 8: Managing AEs Associated with HMA Treatment

January 25th 2024

Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.